Basel Medical Group Ltd Ordinary Shares (BMGL) Revenue History
Annual and quarterly revenue from 2021 to present
BMGL Revenue Over Time (2021–2024)
BMGL Revenue Growth History
2 of 3 years with positive growth- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- -9.0%
- FY2023 revenue growth
- +3.6%
- FY2024 revenue growth
- +12.6%
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $6.1M | — |
BMGL Revenue Analysis (2021–2024)
Current Revenue & Growth
As of June 26, 2026, Basel Medical Group Ltd Ordinary Shares (BMGL) generated trailing twelve-month (TTM) revenue of $6.1 million. The most recent quarter (Q4 2024) recorded $6.1 million in revenue
Historical Growth Trajectory
BMGL's historical revenue data shows a 3-year CAGR of +2.0%. Basel Medical Group Ltd Ordinary Shares's highest annual revenue of $11.3 million was recorded in 2024, an all-time high.
Peer Comparison
Compared to Healthcare sector peers — including ACMR (+19.7% YoY), CLOV (+48.4% YoY), and HCAI. Compare BMGL vs ACMR →
BMGL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BMGLCurrent | $6M | - | - | -19.3% | |
 ACMR | $901M | +19.7% | +41.9% | 12.1% | |
 CLOV | $1.9B | +48.4% | +23.4% | -4.4% | |
 HCAI | $7M | - | - | -322.7% | |
 SGBX | $5M | -42.6% | +10.8% | -195.0% | |
 MD | $1.9B | -2.3% | +2.0% | 12.1% |
BMGL Historical Revenue Data (2021–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $11.3M | +12.6% | $8.8M | 77.7% | $-2,183,015 | -19.3% |
| 2023 | $10.1M | +3.6% | $7.8M | 77.6% | $2.2M | 21.8% |
| 2022 | $9.7M | -9.0% | $7.4M | 75.9% | $2.0M | 20.6% |
| 2021 | $10.7M | - | $8.5M | 79.6% | $2.5M | 23.2% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BMGL — Frequently Asked Questions
Quick answers to the most common questions about buying BMGL stock.
Is BMGL's revenue growth accelerating or slowing?
BMGL TTM revenue: $6M. YoY growth: N/A. 5-year CAGR: N/A.
What is BMGL's revenue history from 2021 to 2026?
Basel Medical Group Ltd Ordinary Shares (BMGL) revenue history spans 2021 to 2026. TTM revenue as of 2026 is $6M, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is BMGL's long-term revenue growth rate (CAGR)?
Basel Medical Group Ltd Ordinary Shares's 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for BMGL.
Why does BMGL's quarterly revenue fluctuate?
BMGL quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Basel Medical Group Ltd Ordinary Shares's revenue data from 2021 to 2026 shows full historical quarterly detail on this page.
How is BMGL's revenue distributed by segment?
BMGL reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does BMGL's revenue compare to industry peers?
Basel Medical Group Ltd Ordinary Shares (BMGL) with TTM revenue of $6M and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.